Egle Therapeutics is a startup.
Egle Therapeutics is a biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to treat autoimmune diseases and cancer. Its pipeline includes clinical-stage candidates such as EGL-003, an IL-2 agonist Treg engager for autoimmune diseases, and EGL-001, an anti-CTLA-4–IL-2m fusion for cancer.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.